Case of Metastatic Basal Cell Carcinoma to Bone Marrow, Resulting in Myelophthisic Anemia

Pham, Catherine M.; Syed, Almas; Siddiqui, Huma; Keller, Richard A.; Kowalewski, Catherine

doi:10.1097/dad.0b013e3182761362

Cited by 14 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our case, the metastasis occurred approximately 6 years after diagnosis of the primary tumor. This correlates well with previous cases ; an MBCC review found the estimated median interval from tumor appearance to metastasis to be 9 years .…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Metastatic basal cell carcinoma caused by carcinoma misdiagnosed as acne – case report and literature review

Aydin

Hölmich

Jakobsen

2016

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

“…In the literature, the median duration between the diagnosis of the primary tumor and the occurrence of metastasis was 18 month (range 1-48 months, N = 9). Two patients had metastases at the time of diagnosis [12,13]. In our case, the metastasis occurred approximately 6 years after diagnosis of the primary tumor.…”

Section: Discussionmentioning

confidence: 78%

Metastatic basal cell carcinoma caused by carcinoma misdiagnosed as acne – case report and literature review

Aydin

Hölmich

Jakobsen

2016

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…In addition, chronic inflammation leading to malignancy (18) and absolute iron deficiency resulting from bleeding (including cancer bleeding) may be responsible for anemia (19). Finally, the suppression of the bone marrow, either by infiltration of malignant cells (20), or myelosuppressive chemotherapy (21), as well as nutrient deficiencies (22) may be associated with anemia. Owing to the potentially multifactorial complexity of anemia, defining causes in cancer patients is not always simple, and conventional evaluation only has a limited value (23).…”

Section: Discussionmentioning

confidence: 99%

Renal failure in cancer patients: results from the national cancer registry of Abidjan, Côte d’Ivoire

Yao¹,

Toure²,

Coulibaly³

et al. 2017

J Nephropathol

View full text Add to dashboard Cite

Background: Renal failure (RF) is a risk factor for morbidity and mortality in cancer patients. Objectives: To describe the profile of cancer patients with RF. Patients and Methods: This is a retrospective descriptive study of RF in patients enrolled in the national cancer registry of Abidjan, during the period from January 2012 to December 2015. The diagnosis of RF was confirmed based on a measured glomerular filtration rate (GFR) < 60 mL/min obtained using the Modification in Diet of Renal Disease (MDRD) formula. A comparison of patients with (n = 131) or without (n = 136) RF, followed by a logistic regression analysis, made it possible to identify the risk factors for RF. Results: The mean age was 54 ± 13.9 years in the group with RF versus 49 ± 14.8 years in the group without RF (P = 0.003). The etiologies of RF were urinary tract obstruction (41.2%), administration of platinum salts (19.8%) and water losses (12.2%). In multivariate analysis, age (P = 0.009), presence of hypertension (P = 0.02), uterine cancer (P = 0.0001) and prostate cancer (P = 0.014) were associated with the risk of RF in cancer patients. Factors such as male gender (P = 0.007), HIV infection (P = 0.021), GFR<15 mL/min (P = 0.002), and hemoglobin level <8 g/dL (P = 0.041) were associated with mortality in cancer patients with RF. Conclusions: Late diagnosis leads to renal complications with an increased risk of mortality.

show abstract

“…There were 312 patients treated with the first line chemotherapy regimens, yet the GC in 188 patients remained in a development condition, and then those patients were treated with the second or/and third line chemotherapy regimens including FOLFIRI and docetaxel single agent. The cycles of chemotherapy used for our GC patients was 4.4±3.705 (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). 286 patients (47.8%) failed to receive further chemotherapy after 1-2 cycles of chemotherapy treatment.…”

Section: Patientsmentioning

confidence: 99%

Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

Zhang

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background：Anaemia is highly prevalent in gastric cancer (GC) patients. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC.Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent or metastatic GCs were unsuitable for surgical resection. Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of cancer-related reduction in haemoglobin was further analysed.Results: Our results revealed that patients with HBini level ≤ 80 g/L had a trend toward a shortened median OS and PFS (p=0.009 and p=0.049, respectively). Interestingly, we also found that HBdec ≥30 g/L was associated with a significantly shortened median OS and PFS (p=0.039 and p=0.001, respectively). Multivariate analysis showed that HBini levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. More importantly, HBdec ≥30 g/L and treatment response were also significantly associated with OS and PFS. Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles.Conclusion: Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥ 30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. Additionally, platinum should not be recommended for treating severely anaemic GC patients.

show abstract

Case of Metastatic Basal Cell Carcinoma to Bone Marrow, Resulting in Myelophthisic Anemia

Abstract: Although the rate of metastasis for BCC is rare, once it occurs, prognosis is poor. MBCC remains a challenge to treat. Therefore, it is critical to resolve the primary BCC and obtain vigilant follow-up, especially in patients with multiple risk factors for MBCC.

Cited by 14 publications

References 19 publications

Metastatic basal cell carcinoma caused by carcinoma misdiagnosed as acne – case report and literature review

Metastatic basal cell carcinoma caused by carcinoma misdiagnosed as acne – case report and literature review

Renal failure in cancer patients: results from the national cancer registry of Abidjan, Côte d’Ivoire

Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

Contact Info

Product

Resources

About